Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

1.

Regenerative Approach to Scars, Ulcers and Related Problems with Fat Grafting.

Klinger M, Lisa A, Klinger F, Giannasi S, Veronesi A, Banzatti B, Bandi V, Catania B, Forcellini D, Maione L, Vinci V, Caviggioli F.

Clin Plast Surg. 2015 Jul;42(3):345-52. doi: 10.1016/j.cps.2015.03.008. Epub 2015 Apr 30. Review.

PMID:
26116940
2.

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.

Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M, Massarut S, Veronesi A.

Radiol Oncol. 2013 Mar;47(1):57-62. doi: 10.2478/raon-2013-0012. Epub 2013 Feb 1.

3.

Facilitating the integration of emotional states in patients' personal disease experience with cancer: a new brief intervention for managing psychological distress.

Annunziata MA, Muzzatti B, Giovannini L, Mella S, Bomben F, Flaiban C, Veronesi A.

Support Care Cancer. 2013 Jul;21(7):1815-9. doi: 10.1007/s00520-013-1735-5. Epub 2013 Feb 9.

PMID:
23397096
4.

Targeting triple negative breast cancer: is p53 the answer?

Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A.

Cancer Treat Rev. 2013 Aug;39(5):541-50. doi: 10.1016/j.ctrv.2012.12.001. Epub 2013 Jan 12. Review.

PMID:
23321033
5.

Negative pigment network: an additional dermoscopic feature for the diagnosis of melanoma.

Pizzichetta MA, Talamini R, Marghoob AA, Soyer HP, Argenziano G, Bono R, Corradin MT, De Giorgi V, Gonzalez MA, Kolm I, Kopf AW, Malvehy J, Nami N, Oliviero M, Pellacani G, Puig S, Rabinovitz H, Rubegni P, Seidenari S, Stanganelli I, Veronesi A, Zalaudek I, Zampieri P, Menzies SW.

J Am Acad Dermatol. 2013 Apr;68(4):552-9. doi: 10.1016/j.jaad.2012.08.012. Epub 2012 Oct 9.

PMID:
23062610
6.

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series.

Di Lauro V, Torrisi E, Bidoli E, Quitadamo D, Cecco S, Veronesi A.

J Oncol. 2012;2012:198412. doi: 10.1155/2012/198412. Epub 2012 Mar 26.

7.

Emotional distress and needs in Italian cancer patients: prevalence and associations with socio-demographic and clinical factors.

Annunziata MA, Muzzatti B, Bidoli E, Veronesi A.

Tumori. 2012 Jan-Feb;98(1):119-25. doi: 10.1700/1053.11510.

PMID:
22495712
8.

Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.

Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A.

Tumori. 2012 Jan-Feb;98(1):33-8. doi: 10.1700/1053.11497.

PMID:
22495699
9.

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.

Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A.

Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review.

10.

Target therapy in elderly breast cancer patients.

Carli P, Turchet E, Quitadamo D, Spada A, Miolo G, Lamaj E, Spazzapan S, Di Lauro V, Dolcetti R, Veronesi A, Crivellari D.

Crit Rev Oncol Hematol. 2012 Sep;83(3):422-31. doi: 10.1016/j.critrevonc.2011.12.004. Epub 2012 Jan 17. Review.

PMID:
22257652
11.

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.

Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R.

Breast Cancer Res. 2011;13(6):R117. doi: 10.1186/bcr3060.

12.

Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?

Miolo G, Bidoli E, Lombardi D, Santeufemia DA, Capobianco G, Dessole F, Scalone S, Spazzapan S, Sorio R, Tabaro G, Veronesi A.

Arch Gynecol Obstet. 2012 Feb;285(2):499-503. doi: 10.1007/s00404-011-1976-9. Epub 2011 Jul 7.

PMID:
21735184
13.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.

Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.

PMID:
21354370
14.

Therapeutic management of breast cancer in the elderly.

Spazzapan S, Crivellari D, Bedard P, Lombardi D, Miolo G, Scalone S, Veronesi A.

Expert Opin Pharmacother. 2011 Apr;12(6):945-60. doi: 10.1517/14656566.2011.540570. Epub 2011 Feb 16. Review.

PMID:
21323593
15.

Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study.

Lombardi D, Scalone S, Crivellari D, Magri MD, La Mura N, Miolo G, Murrone A, Perin T, Coran F, Candiani E, Massarut S, Veronesi A.

Tumori. 2010 Mar-Apr;96(2):229-33.

16.

Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.

Veronesi A, Miolo G, Magri MD, Crivellari D, Scalone S, Bidoli E, Lombardi D.

BMC Cancer. 2010 May 14;10:205. doi: 10.1186/1471-2407-10-205.

17.

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.

Miolo G, Baldo P, Bidoli E, Lombardi D, Scalone S, Sorio R, Veronesi A.

Tumori. 2009 Nov-Dec;95(6):687-90.

18.

Screening: is breast cancer overdiagnosed?

Veronesi A, Serraino D.

Nat Rev Clin Oncol. 2009 Dec;6(12):682-3. doi: 10.1038/nrclinonc.2009.172.

PMID:
19942923
19.

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.

Miolo G, Canzonieri V, De Giacomi C, Puppa LD, Dolcetti R, Lombardi D, Perin T, Scalone S, Veronesi A, Viel A.

BMC Cancer. 2009 Oct 10;9:360. doi: 10.1186/1471-2407-9-360.

20.

Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.

De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, Fantin D, Bertuzzi CA, Fabiani F, Morassut S, Bidoli E, Veronesi A.

Ann Oncol. 2009 Dec;20(12):1936-42. doi: 10.1093/annonc/mdp235. Epub 2009 Jun 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk